Laurus Labs Ltd Analyst Rating
based on 14 analysts
46.67%
Buy
6.67%
Hold
46.67%
Sell
Based on 14 analysts offering long term price targets for Laurus Labs Ltd. An average target of ₹418.36
Source: S&P Global Market Intelligence
Laurus Labs Ltd Share analysis
Laurus Labs Ltd price forecast by 14 analysts
Downside of
High
₹531
Target
₹418.36
Low
₹293
Laurus Labs Ltd target price ₹418.36, a slight downside of -14.45% compared to current price of ₹489.15. According to 14 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Laurus Labs Ltd revenue growth forecast
Expected growth rate Q1, FY2026:28.18%
Forecast
Actual
Including amortisation and stock based compensations
Laurus Labs Ltd EPS growth forecast
EPS estimate Q1, FY2026:258.72%
Forecast
Actual
Source: S&P Global Market Intelligence
Laurus Labs Ltd Performance
Day's Low
Day's High
₹482.6₹491.6552 Week's Low
52 Week's High
₹360.85₹518
| Returns % | |
| 1 Month Return | + 5.1 % |
| 3 Month Return | + 10.09 % |
| 1 Year Return | + 30.85 % |
| Market Stats | |
| Previous Close | ₹489.00 |
| Open | ₹488.95 |
| Volume | 6.82L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹26,364.89Cr |
Laurus Labs Ltd Key Statistics
| P/E Ratio | 201.23 |
| PEG Ratio | -45.74 |
| Market Cap | ₹26,364.89 Cr |
| P/B Ratio | 5.02 |
| EPS | 3.12 |
| Dividend Yield | 0.2 |
| Sector | Pharmaceuticals |
| ROE | 5.41 |
Laurus Labs Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹26,364.89 Cr | 126.87% | 0.67 | ₹168 Cr | ₹5,040 Cr | |
| HOLD | ₹25,420.21 Cr | 18.47% | 0.55 | ₹362 Cr | ₹2,226 Cr | |
| HOLD | ₹66,117.05 Cr | 32.89% | 0.56 | ₹1,811 Cr | ₹12,667 Cr | |
| BUY | ₹10,968.52 Cr | 14.47% | 0.64 | ₹119 Cr | ₹547 Cr | |
| BUY | ₹5,102.04 Cr | 14.44% | 0.54 | ₹69 Cr | ₹571 Cr |
About Laurus Labs Ltd
Share Price: ₹489.15 per share as on 21 Nov, 2024 04:01 PM
Market Capitalisation: ₹26,364.89Cr as of today
Revenue: ₹1,223.70Cr as on September 2024 (Q3 24)
Net Profit: ₹17.72Cr as on September 2024 (Q3 24)
Listing date: 19 Dec, 2016
Chairperson Name: M V G Rao
| Organisation | Laurus Labs Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Laurus Labs Ltd
Laurus Labs Participates in Green Pharma City Review - 08 Nov, 2024
Madan Mohan Reddy from Laurus Labs, along with representatives from other pharma companies, attended a review meeting on the Green Pharma City project in Hyderabad.
Laurus Labs Enhances R&D and Manufacturing Capabilities - 04 Nov, 2024
Laurus Labs is focusing on R&D with 62 products in the pipeline and has opened a new small molecule R&D center in Hyderabad. The company aims to enhance its manufacturing capabilities and has successfully passed multiple quality audits, positioning itself as a diversified CDMO.
Laurus Labs: Analyst Picks for Muhurat Trading 2024 - 01 Nov, 2024
Market expert Soni Patnaik recommends Laurus Labs for Muhurat Trading 2024, projecting a 12% upside with a target price of Rs 530. Despite a 46% decline in net profit for Q2FY25, the stock has shown positive returns, up 9% in six months and 13% year-to-date.
Laurus Labs Focuses on CDMO for Growth - 28 Oct, 2024
Laurus Labs' CEO emphasizes the CDMO and API segments as growth drivers, with a 40% sequential revenue increase in CDMO. However, revenue misses estimates due to weak Generic API demand, prompting a target price reduction.
Laurus Labs Reports Mixed Q2 Results, Shares Surge - 25 Oct, 2024
Laurus Labs reported a significant decline in Q2 net profit to ₹17.72 crore, with flat revenue. Despite this, shares surged due to stable sales expectations and improved margin guidance for H2 FY25, alongside a notable increase in trading volume.
Laurus Labs Reports Significant Profit Decline in Q2 - 24 Oct, 2024
Laurus Labs announced its Q2 FY25 results, revealing flat revenue but a significant 55% drop in net profit. The company missed analysts' expectations, reporting a 46% decline in net profit to ₹20 crore compared to the previous year.
Laurus Labs Shows Potential After Recent Decline - 14 Oct, 2024
Laurus Labs has experienced a decline of over 10% from its 52-week high of Rs 517 reached on September 10, 2024. Recent price movements indicate potential for recovery, making it an attractive option for high-risk short-term traders targeting above Rs 500 in the coming weeks.
Insights on Laurus Labs Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 2 quarters, 1.19K Cr → 1.22K Cr (in ₹), with an average increase of 2.5% per quarter
- POSITIVE IMPACT
Price Rise
In the last 1 month, LAURUSLABS stock has moved up by 5.1%
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 25.67% to 26.08% in Sep 2024 quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 33.59% to 33.69% in Sep 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 12.51 Cr → 19.84 Cr (in ₹), with an average increase of 37.0% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 130.6% return, outperforming this stock by 127.0%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 58.6% return, outperforming this stock by 27.7%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 27.18% of holdings in Sep 2024 quarter
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 9.18% to 8.25% in Sep 2024 quarter
Laurus Labs Ltd Financials
Index Inclusions
Laurus Labs Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 27.18% | 0.00 | |
| Foreign Institutions | 26.08% | 1.60 | |
| Mutual Funds | 8.25% | ||
| Retail Investors | 33.69% | 0.30 | |
| Others | 4.8% | 9.51 |
Laurus Labs Ltd Key Indicators
Laurus Labs Ltd Valuation
Laurus Labs Ltd in the last 5 years
Lowest (16.96x)
March 28, 2023
Industry (54.42x)
November 19, 2024
Today (201.23x)
November 19, 2024
Highest (205.68x)
November 1, 2024
Laurus Labs Ltd Earnings and Dividends
Laurus Labs Ltd Earnings Results
Laurus Labs Ltd’s net profit fell -46.31% since last year same period to ₹19.84Cr in the Q2 2024-2025. On a quarterly growth basis, Laurus Labs Ltd has generated 58.59% jump in its net profits since last 3-months.
Read More about Earnings ResultsLaurus Labs Ltd Dividends October,2024
In the quarter ending September 2024, Laurus Labs Ltd has declared dividend of ₹0.40 - translating a dividend yield of 0.16%.
Read More about Dividends
Laurus Labs Ltd Technicals Summary
Bearish
Neutral
Bullish
Laurus Labs Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Laurus Labs Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Laurus Labs Ltd shares.
Laurus Labs Ltd (LAURUSLABS) share price today is ₹489.15
Laurus Labs Ltd is listed on NSE
Laurus Labs Ltd is listed on BSE
- Today’s highest price of Laurus Labs Ltd is ₹491.65.
- Today’s lowest price of Laurus Labs Ltd is ₹482.6.
PE Ratio of Laurus Labs Ltd is 201.23
PE ratio = Laurus Labs Ltd Market price per share / Laurus Labs Ltd Earnings per share
Today’s traded volume of Laurus Labs Ltd(LAURUSLABS) is 6.82L.
Today’s market capitalisation of Laurus Labs Ltd(LAURUSLABS) is ₹26364.89Cr.
| Laurus Labs Ltd(LAURUSLABS | Price |
|---|---|
52 Week High | ₹518 |
52 Week Low | ₹360.85 |
Laurus Labs Ltd(LAURUSLABS) share price is ₹489.15. It is down -5.57% from its 52 Week High price of ₹518
Laurus Labs Ltd(LAURUSLABS) share price is ₹489.15. It is up 35.55% from its 52 Week Low price of ₹360.85
| Laurus Labs Ltd(LAURUSLABS | Returns |
|---|---|
1 Day Returns | 0.15% |
1 Month Returns | 5.1% |
3 Month Returns | 10.09% |
1 Year Returns | 30.85% |